Presentation is loading. Please wait.

Presentation is loading. Please wait.

ERAP1 allotype combinations from CD8/TILlow tumors have reduced trimming activity. ERAP1 allotype combinations from CD8/TILlow tumors have reduced trimming.

Published byAnaïs Généreux Modified over 5 years ago

Similar presentations

Presentation on theme: "ERAP1 allotype combinations from CD8/TILlow tumors have reduced trimming activity. ERAP1 allotype combinations from CD8/TILlow tumors have reduced trimming."— Presentation transcript:

1 ERAP1 allotype combinations from CD8/TILlow tumors have reduced trimming activity.
ERAP1 allotype combinations from CD8/TILlow tumors have reduced trimming activity. A, The total trimming activity for all 20 X-SHL8 substrates for each allotype combination were combined and grouped into CD8/TIL status. Overall trimming for each CD8/TIL group is represented as AUC. B, Table showing both the individual AUC for allotype pairs in each CD8/TIL group and the mean for each group. C, Specificity of ERAP1 trimming activity from those found exclusively in CD8/TILhigh, CD8/TILmoderate, or CD8/TILlow tumors towards X-SHL8 amino acids grouped based on physicochemical properties; basic, acidic, polar uncharged, aliphatic, aromatic, and special. Data from A–C, pooled from 4 independent experimental repeats ± SEM (***, P ≤ 0.001; **, P ≤ 0.01; *, P ≤ 0.05). Emma Reeves et al. Cancer Immunol Res 2019;7: ©2019 by American Association for Cancer Research

Download ppt "ERAP1 allotype combinations from CD8/TILlow tumors have reduced trimming activity. ERAP1 allotype combinations from CD8/TILlow tumors have reduced trimming."

Similar presentations

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).

IHC staining of FFPE esophageal tissues in tissue microarrays (×20).
Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.

Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.
Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.
H31m1-PDL1 cells form progressively growing tumors in WT mice.

H31m1-PDL1 cells form progressively growing tumors in WT mice.
Cetuximab treatment increases IFNγ receptor 1 expression.

Cetuximab treatment increases IFNγ receptor 1 expression.
Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.

Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.
Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.

Kinetic changes of sPD-L1 and cytokines, and kinetic radiographic reduction in tumor size after ipilimumab plus bevacizumab treatment. Kinetic changes.
Caspase-1 from myeloid cells induces tumor proliferation via MyD88 oncogenic signaling. Caspase-1 from myeloid cells induces tumor proliferation via MyD88.

Caspase-1 from myeloid cells induces tumor proliferation via MyD88 oncogenic signaling. Caspase-1 from myeloid cells induces tumor proliferation via MyD88.
ROC curve for separating advanced stages (advanced BE and EA) versus early stages (BE or BE instability) using total genome-wide LOH [area under the curve.

ROC curve for separating advanced stages (advanced BE and EA) versus early stages (BE or BE instability) using total genome-wide LOH [area under the curve.
ERAP1 allotypes shape the epitope repertoire of virus-specific CD8+ T cell responses in acute hepatitis C virus infection  Janine Kemming, Emma Reeves,

ERAP1 allotypes shape the epitope repertoire of virus-specific CD8+ T cell responses in acute hepatitis C virus infection  Janine Kemming, Emma Reeves,
Anti-CD96 combines with anti–CTLA-4 or anti–PD-1 to suppress experimental and spontaneous lung metastases. Anti-CD96 combines with anti–CTLA-4 or anti–PD-1.

Anti-CD96 combines with anti–CTLA-4 or anti–PD-1 to suppress experimental and spontaneous lung metastases. Anti-CD96 combines with anti–CTLA-4 or anti–PD-1.
Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.

Highly related T9 and T3 sarcoma cells show distinct tumor growth patterns but similar PD-L1 expression kinetics in vivo. Highly related T9 and T3 sarcoma.
Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. (A)

Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. (A)
Mouse lymphoma model. Mouse lymphoma model. A, EL-Arf−/− cells (1 × 106) were tail-vein injected into C57BL/6 mice. LNIWC imaging was separated into 2.

Mouse lymphoma model. Mouse lymphoma model. A, EL-Arf−/− cells (1 × 106) were tail-vein injected into C57BL/6 mice. LNIWC imaging was separated into 2.
Exosome-mediated inhibition of T cells is reversible.

Exosome-mediated inhibition of T cells is reversible.
Gene expression changes associated with response to combination CPI-444 and anti–PD-L1 treatment in MC38 tumors. Gene expression changes associated with.

Gene expression changes associated with response to combination CPI-444 and anti–PD-L1 treatment in MC38 tumors. Gene expression changes associated with.
Protection from 4T1 tumor rechallenge in treated mice.

Protection from 4T1 tumor rechallenge in treated mice.
L-ICON1 is effective for the treatment of murine TNBC (4T1/Luc + GFP) in an orthotopic CDX model. L-ICON1 is effective for the treatment of murine TNBC.

L-ICON1 is effective for the treatment of murine TNBC (4T1/Luc + GFP) in an orthotopic CDX model. L-ICON1 is effective for the treatment of murine TNBC.
The TSDR of ATL cells exhibits Treg-like hypomethylated status or CD4+ conventional T cell–like methylated status. The TSDR of ATL cells exhibits Treg-like.

The TSDR of ATL cells exhibits Treg-like hypomethylated status or CD4+ conventional T cell–like methylated status. The TSDR of ATL cells exhibits Treg-like.
Frequency and kinetics of killer cell apoptosis are dependent on functional conjugations with multiple NALM-6 tumor cells. Frequency and kinetics of killer.

Frequency and kinetics of killer cell apoptosis are dependent on functional conjugations with multiple NALM-6 tumor cells. Frequency and kinetics of killer.

Similar presentations

Ads by Google